Skip to content
Menu

Kenvue Inc KVUE

Full chart Compare
Set alert

Price alert · KVUE

All alert types
19.31 USD -0.25 (-1.28%)

Regular-session close

19.60 +0.29 +1.50%

After hours · Oct 30, 4:00 PM ET

19.20 Day range 20.00
15.94 52-week range 20.13
YTD
0.00%
1 year
0.00%
Market cap
37.11B
Revenue (ttm)
15.53B
Profit margin
10.88%
EPS (ttm)
0.88
Shares out
1.92B
P/E ratio
21.94
Forward P/E
15.58
Dividend
0.84 (4.35%)
Ex-dividend date
Sep 21, 2026
YTD return
0.00%
1-year return
0.00%
Volume
66.38M
Avg volume
22.41M
Open
19.99
Previous close
19.56
Day's range
19.20 – 20.00
52-week range
15.94 – 20.13
Beta
0.40
Analysts
Hold
Price target
19.50 (+1.0%)
Earnings date
Feb 16, 2027

 

No chart data for this range yet.

Key statistics

Enterprise value
44.41B
PEG ratio
1.53
Price / sales
2.39
Price / book
3.65
Dividend yield
4.35%
Payout ratio
94.60%
Revenue growth
3.20%
Free cash flow
2.77B
Total cash
1.04B
Total debt
8.34B
Return on equity
16.25%
Short % of float
3.36%
50-day average
18.40
200-day average
18.22

Financials — quick view

All financials
KVUE Revenue — quarterly 3.89B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
KVUE Net income — quarterly 430.00M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
KVUE EPS — quarterly 0.22
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

KVUE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 16, 2027Dec 27, 20260.28———
Oct 30, 2026Sep 27, 20260.29150.290.00-0.51%
Aug 6, 2026Jun 28, 20260.31870.31-0.01-2.73%
May 7, 2026Mar 29, 20260.26210.32+0.06+22.09%
Feb 17, 2026Dec 28, 20250.22270.27+0.05+21.24%
Nov 3, 2025Sep 28, 20250.26020.28+0.02+7.61%

Upgrades / downgrades

KVUE analyst upgrades and downgrades
DateFirmActionFromTo
Nov 2, 2026UBSmainNeutralNeutral
Aug 11, 2026UBSmainNeutralNeutral
Jul 21, 2026BarclaysmainEqual-WeightEqual-Weight
Jul 16, 2026UBSmainNeutralNeutral
Apr 15, 2026CitigroupmainNeutralNeutral
Apr 14, 2026BarclaysmainEqual-WeightEqual-Weight

About Kenvue Inc

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

Sector
Consumer Defensive
Industry
Household & Personal Products
Country
United States
Website
kenvue.com

News

Your note

Sign in to keep a note on KVUE — it syncs with the Stock Master app.

Insider holders

KVUE insider holders
InsiderRelationLatest transactionDateShares held
ALVARADO LUANIChief Operating OfficerConversion of Exercise of derivative securityMar 9, 202661,415
LAWSON CARLTONOfficerStock Award(Grant)Oct 1, 2026148,012
MONGON THIBAUTChief Executive OfficerConversion of Exercise of derivative securityMar 4, 2025216,469
PERRY KIRK LChief Executive OfficerConversion of Exercise of derivative securityDec 14, 202562,554
RUH PAULChief Financial OfficerConversion of Exercise of derivative securityMar 4, 202556,198
SMITH JEFFREY CHADDirectorPurchaseDec 11, 20250

Institution ownership

KVUE institution ownership
Holder% heldSharesValueReported
FMR, LLC8.18%157,051,4183.03BJun 29, 2026
Blackrock Inc.7.85%150,825,6942.91BJun 29, 2026
Vanguard Capital Management LLC6.52%125,314,5642.42BJun 29, 2026
State Street Corporation6.33%121,619,0542.35BJun 29, 2026
Vanguard Portfolio Management LLC4.86%93,303,7621.80BJun 29, 2026
Geode Capital Management, LLC2.71%52,021,3201.00BJun 29, 2026

Fund ownership

KVUE fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%60,959,2571.18BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%49,756,164960.79MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund2.17%41,604,311803.38MJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%25,594,358494.23MSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%24,923,436481.27MAug 30, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.24%23,820,542459.97MSep 29, 2026